A new study published in Pediatrics has many people worried that Tdap vaccination strategies may get a lot more aggressive. The study shows that the Tdap vaccine’s ‘protection’ falls off exponentially every year, leaving those that took it ‘unprotected.’ The actual effectiveness of the vaccine fell to just 9% after 4 years.
For the study, researchers assessed Tdap efficacy among adolescents within Kaiser Permanente Northern California during pertussis outbreaks in 2010 and 2014. Tdap coverage was seen in over 90% of adolescents but they exhibited the highest incidence of pertussis of any age group in 2014. Study authors noted that routine vaccination at ages 11–12 did not prevent the epidemic. Moreover, an increasing number of adolescents who have received only the newer acellular pertussis vaccines remain at higher risk of contracting whooping cough.
Nicola Klein, MD,PhD, co-director of the Kaiser Permanente Vaccine Study Center, stated that Tdap may contain whooping cough “more effectively if it is administered to adolescents in anticipation of a local outbreak rather than on a routine basis at age 11 or 12.” (source)
I do not see any way that pharmaceutical companies will ever allow what Klein is proposing. Pharmaceutical companies are likely to instead assert more vaccines are needed. They will be able to make a case that falling numbers are an indication that a more aggressive Tdap vaccination schedule would solve the issue. In a clear cut case proving failure on the part of the Tdap maker, pharma has actually been placed in a position to create more revenue. Rather than being subjected to further scrutiny over not delivering as promised and based on the theory of vaccination, failing to protect the people of the world, they will most likely be rewarded with furthering government overreach that pushes more vaccines on more humans. A failed study turned opportunity for vaccine makers is the saddest of things.
The FDA has already admitted that vaccines cause SIDS. It’s on the insert. (source)
In the German case-control study and US open-label safety study in which 14,971 infants received Tripedia vaccine, 13 deaths in Tripedia vaccine recipients were reported. Causes of deaths included seven SIDS, and one of each of the following: enteritis, Leigh Syndrome, adrenogenital syndrome, cardiac arrest, motor vehicle accident, and accidental drowning. All of these events occurred more than two weeks post immunization.2 The rate of SIDS observed in the German case-control study was 0.4/1,000 vaccinated infants. The rate of SIDS observed in the US open-label safety study was 0.8/1,000 vaccinated infants and the reported rate of SIDS in the US from 1985-1991 was 1.5/1,000 live births.34 By chance alone, some cases of SIDS can be expected to follow receipt of whole-cell pertussis DTP35 or DTaP vaccines.
It also was responsible for a whooping cough outbreak in Florida. At what point to we start to “get it?”
Of course, what I’m proposing hasn’t been stated by any pharmaceutical company nor has the CDC made any statements regarding creating a more aggressive Tdap schedule, but I firmly believe the writing is now on the wall. The opportunistic pattern on behalf of pharma has a history we can all see clearly. Pharma is great at creating opportunity in what often seems like clear cut negligence. Even in cases of vaccine deaths, pharma can assert that more vaccine is needed.
Take this example of a mother who posted a video of her baby’s whooping cough battle. She readily admits the baby HAS BEEN VACCINATED yet, pleas with others to get their babies vaccinated also.
THIS is the absurdity that is big pharma. They create opportunity out of famine and suffering and negligence. And that’s what I think this new study is for them: opportunity.